IPO Snapshot
Key metrics and details at a glance.
Price Band
₹807
Per ShareLot Size
18 Shares
Minimum Investment
₹14,526
Issue Size
₹939.7 Cr
Face Value
₹1
Per ShareIPO Type
Book Building
Retail Quota
35%
QIB Quota
50%
NII Quota
15%
IPO Timeline
Important dates for your applying strategy.
Subscription Status
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Molbio Diagnostics Ltd
Business model, operations, and market positioning.
About the Company
We are an innovative point-of-care diagnostics company focused on expanding access to accurate, rapid and costeffective healthcare technologies to diagnose infectious and non-communicable diseases. Our portable and battery operated `Truenat' platform facilitates diagnosis using our disease-specific `Truenat' test kits within an hour and enables screening and diagnosis for 30 diseases, including tuberculosis, COVID, Hepatitis B and C, Human immunodeficiency virus, and Human Papillomavirus, as of March 31, 2025. We also offer devices, enabling radiology, digital pathology and breast health screening. We offer our products globally to public health programs, diagnostic laboratories, and private and public hospitals.
Industry Overview
The global point-of-care testing ("POCT") market stands at Rs.2,350.8 billion (infectious and non-infectious diseases), projected to grow at 18.7% CAGR to reach at Rs.5,555.6 billion by 2029. Infectious disease testing constitutes 31.4% of the global POCT market. POCT market in India stands at approximately Rs.198.5 billion in Fiscal 2025, projected to grow at 17.3% CAGR to reach at approximately 440.9 billion by Fiscal 2030. Of which, the infectious POCT market is estimated to have a market potential of Rs.88.2 billion in Fiscal 2025 and is projected to reach Rs. 236.6 billion by Fiscal 2030.
Company History
Our Company was originally incorporated as `Molbio Diagnostics Private Limited' at Panaji, as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated October 20, 2000, issued by the RoC. Thereafter, our Company was converted from a private limited company to a public limited company, pursuant to a resolution passed in the extraordinary general meeting of our Shareholders held on November 22, 2024, and the name of our Company was changed to Molbio Diagnostics Limited, and a fresh certificate of incorporation dated January 16, 2025 was issued to our Company by the RoC.
Growth Strategy
- Expand our geographical presence in India and across the globe.
- Continue to expand our suite of diagnostic solutions for multiple diseases.
- Develop new POC platforms for other communicable and non-communicable diseases.
- Grow through strategic acquisitions and alliances and establish a centre of excellence.
Promoter Holding (Pre-Issue)
44.89%
Promoter Holding (Post-Issue)
38.25%
Issue Type
Book Building
ISIN
INE869T01028
Financial Performance
Revenue, profit, and asset growth over the last three financial years.
Data presented in crores for FY20 to FY24.
Objects of the Issue
How the company plans to utilize IPO proceeds.
The funds raised through this IPO will be used for:
Initial public offering of up to 11,644,314 equity shares of face value of Re. 1 each of the company ("Equity Shares") for cash at a price of Rs. 807 per equity share (including a share premium of Rs. 806 per equity share) ("Offer Price") aggregating up to Rs. 939.70 Crores ("Offer"). The offer comprises a fresh issue of up to 2,478,314 equity shares of face value of Re. 1 each aggregating up to Rs. 200.00 Crores ("Fresh Issue") and an offer for sale of up to 9,166,000 equity shares of face value of Re. 1 each ("Offered Shares") aggregating up to Rs. 739.70 Crores, comprising up to 1,811,000 equity shares of face value of Re. 1 each aggregating up to Rs. 146.15 Crores by Exxora Trading LLP, up to 1,221,000 equity shares of face value of Re. 1 each aggregating up to Rs. 98.53 Crores by Chandrasekhar Bhaskaran Nair (Jointly Held with Anita Angela Chandrasekhar), up to 48,000 equity shares of face value of Re. 1 each aggregating up to Rs. 3.87 Crores by Abdul Qadir Mohamed Theruvath, up to 193,000 equity shares of face value of Re. 1 each aggregating up to Rs. 15.58 Crores by Chewbacca Services Limited, up to 902,000 equity shares of face value of Re. 1 each aggregating up to Rs. 72.79 Crores by J. Guru Dutt (Jointly Held with Sandhya Guru Dutt), up to 1,125,000 equity shares of face value of Re. 1 each aggregating up to Rs. 90.79 Crores by Gopalkrishna Mangalore Kini, up to 902,000 equity shares of face value of Re. 1 each aggregating up to Rs. 72.79 Crores by Gopalakrishna Sampathgiri (Jointly Held with Jayshree Sampathgiri), up to 1,000,000 equity shares of face value of Re. 1 each aggregating up to Rs. 80.7 Crores by India Business Excellence Fund III, up to 17,000 equity shares of face value of Re. 1 each aggregating up to Rs. 1.37 Crores by M Ganesh Kamath, up to 248,000 equity shares of face value of Re. 1 each aggregating up to Rs. 20.01 Crores by M.A. Rohit, up to 202,000 equity shares of face value of Re. 1 each aggregating up to Rs. 16.30 Crores by M.A. Sharath, up to 451,000 equity shares of face value of Re. 1 each aggregating up to Rs. 36.40 Crores by M.A. Usha Rani, up to 452,000 equity shares of face value of Re. 1 each aggregating up to Rs. 36.48 Crores by Sangeetha M Kini, up to 97,000 equity shares of face value of Re. 1/- each aggregating up to Rs. 7.83 Crores by Shaheeda Abdul Kader, up to 226,000 equity shares of face value of Re. 1 each aggregating up to Rs. 18.24 Crores by Shruti G Kini, up to 193,000 equity shares of face value of Re. 1 each aggregating up to Rs. 15.58 Crores by Sujay Limited, up to 78,000 equity shares of face value of Re. 1 each aggregating up to Rs. 6.29 Crores by V Sciences Investments Pte. Ltd., and up to 78,000 equity shares of face value of Re. 1/- each aggregating up to Rs. [*] crores by Vivek Devaraj (together, the "Selling Shareholders", and such offer for sale of equity shares by the selling shareholders, the "Offer for Sale"). This offer includes a reservation of up to 18,587 equity shares of face value of Re. 1/- each aggregating up to Rs. 1.5 (constituting up to [*]% of the post-offer paid-up equity share capital) for subscription by eligible employees (the "Employee Reservation Portion"). The company in consultation with the brlms, may offer a discount of Rs 76 per equity share of face value of Re. 1 each, to eligible employees bidding in the employee reservation portion ("Employee Discount"), subject to necessary approvals as may be required the offer less the employee reservation portion is hereinafter referred to as the "Net Offer". The offer and the net offer would constitute [*]% and [*]%, respectively, of the company post-offer paid-up equity share capital. Price Band: Rs. 807 per equity share of face value of Rs. 1 each. The floor price 807 times the face value of the equity shares, respectively. Bids can be made for a minimum of 18 equity shares of face value of Rs. 1 each and in multiples of 18 equity shares of face value of Rs. 1 each thereafter. A discount of Rs. 76.00 per equity share is being offered to eligible employees bidding in the employee reservation portion.
*Subject to approvals and market conditions.
- We are well placed to address unmet demand in a large and growing molecular diagnostic market with gaining credence of point-of-care testing.
- Innovative, R&D focussed business.
- We have developed and commercialized a novel portable multi-disease point-of-care molecular diagnostics platform.
- We have a scalable business model with strong entry barriers, high proportion of recurring revenues and a growing suite of tests.
- Our strategic collaborations and acquisitions enhance our capabilities and offerings.
- The company derives a portion of its revenues from the sale of the company's products to the Indian central and state governments, and international aid agencies for their public healthcare programs. The company's revenue from such government and international aid agencies was 84.56%, 87.83% and 91.60% of its revenue from contracts with customers - sale of products - finished goods in Fiscals 2026, 2025 and 2024, respectively. Any unfavourable policy changes by these agencies or a decrease in funding for public healthcare programs may impact the sale of the company's products and adversely affect its business, financial condition, results of operations and cash flows. Further, the company's revenue from the top 10 customers was 83.26%, 83.62% and 78.54% of its revenue from contracts with customers - sale of products - finished goods in Fiscals 2026, 2025 and 2024, respectively. The loss of any of these customers or a decline in demand for the company's products from them could also have an adverse effect on its business, financial condition, results of operations and cash flows.
- The company derives a portion of its revenues from the sale of diagnostic test kits for tuberculosis ("TB"). Its revenue from the sale of test kits for TB was 70.20%, 69.11% and 62.40% of the company's revenue from contracts with customers - sale of products - finished goods in the Fiscals 2026, 2025 and 2024, respectively. Any decline in the demand for such test kits may have an adverse effect on the company's business, financial condition, results of operation and cash flows.
- The company has invested and intend to continue to invest in research and development ("R&D") efforts to grow its menu of tests. The company cannot assure you that its R&D efforts will result in the successful development and obtaining of government approvals for new tests, which could adversely affect its business, results of operations, and cash flows.
- The company's Subsidiaries, Prognosys Medical Systems Private Limited, Prognosys Healthcare (India) Private Limited and OptraScan INC, have incurred losses in the past and may incur losses in the future which could have an adverse effect on its business, financial condition, results of operations and cash flows. Further, the Company (on a consolidated basis) and some of its Subsidiaries have experienced negative cash flows from operating activities in the past. Any such negative cash flows in the future could affect the company's business, results of operations, financial condition and cash flows.
- The company's Promoters (certain of whom are also Directors) hold Equity Shares in the Company and may be interested in the Company's performance in addition to any remuneration and reimbursement of expenses payable to them.